Role of DNMT3A, TET2, and IDH1/2 Mutations in Pre-leukemic Stem Cells in Acute Myeloid Leukemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2013 Aug 17

PMID 23949914

Citations 61

Authors

Steven M Chan

Ravindra Majeti

Affiliations

Soon will be listed here.

Abstract

Aberrant changes in the epigenome are now recognized to be important in driving the development of multiple human cancers including acute myeloid leukemia. Recent advances in sequencing technologies have led to the identification of recurrent mutations in genes that regulate DNA methylation including DNA methyltransferase 3A (DNMT3A), ten-eleven translocation 2 (TET2), and isocitrate dehydrogenase 1 (IDH1) and IDH2. These mutations have been shown to promote self-renewal and block differentiation of hematopoietic stem/progenitor cells. Acquisition of these mutations in hematopoietic stem cells can lead to their clonal expansion resulting in a pre-leukemic stem cell (pre-LSC) population. Pre-LSCs retain the ability to differentiate into the full spectrum of mature daughter cells but can become fully transformed with the acquisition of additional driver mutations. Here, we review the effects of mutations in DNMT3A, TET2, and IDH1/2 on mouse and human hematopoiesis, the current understanding of their role in pre-LSCs, and therapeutic strategies to eliminate this population which may serve as a cellular reservoir for relapse.

Citing Articles

Overexpression of miR-99a promoted expansion and suppressed differentiation of hematopoietic stem/progenitor cells.

Wang W, Hao X, Lv X, Li Y, Xing W, Chen T Sci Rep. 2025; 15(1):8890.

PMID: 40087327 DOI: 10.1038/s41598-025-92827-7.

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis.

Urrutia S, Kantarjian H, Ravandi-Kashani F, Bueso-Ramos C, Kanagal-Shamanna R, Jabbour E J Hematol Oncol. 2024; 17(1):112.

PMID: 39548557 PMC: 11568598. DOI: 10.1186/s13045-024-01630-w.

Precision medicine in AML: overcoming resistance.

Urrutia S, Takahashi K Int J Hematol. 2024; 120(4):439-454.

PMID: 39085680 DOI: 10.1007/s12185-024-03827-8.

Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targets.

Gao X, Zuo X, Min T, Wan Y, He Y, Jiang B Front Pharmacol. 2024; 15:1388903.

PMID: 38895633 PMC: 11183326. DOI: 10.3389/fphar.2024.1388903.

Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.

Shi Y, Chen X, Jin H, Zhu L, Hong M, Zhu Y Ann Hematol. 2024; 103(7):2323-2335.

PMID: 38722387 DOI: 10.1007/s00277-024-05786-w.

References

Pandolfi A, Barreyro L, Steidl U . Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med. 2013; 2(2):143-50. PMC: 3659760. DOI: 10.5966/sctm.2012-0109. View

Challen G, Sun D, Jeong M, Luo M, Jelinek J, Berg J . Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011; 44(1):23-31. PMC: 3637952. DOI: 10.1038/ng.1009. View

Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-33. PMC: 3201818. DOI: 10.1056/NEJMoa1005143. View

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

Chowdhury R, Yeoh K, Tian Y, Hillringhaus L, Bagg E, Rose N . The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011; 12(5):463-9. PMC: 3090014. DOI: 10.1038/embor.2011.43. View

Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. PMC: 2818760. DOI: 10.1038/nature08617. View

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View

Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E . Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 2012; 27(5):1044-52. DOI: 10.1038/leu.2012.317. View

Chou W, Chou S, Liu C, Chen C, Hou H, Kuo Y . TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011; 118(14):3803-10. DOI: 10.1182/blood-2011-02-339747. View

10.

Borger D, Tanabe K, Fan K, Lopez H, Fantin V, Straley K . Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2011; 17(1):72-9. PMC: 3267826. DOI: 10.1634/theoncologist.2011-0386. View

11.

Tefferi A, Levine R, Lim K, Abdel-Wahab O, Lasho T, Patel J . Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009; 23(5):900-4. PMC: 4654631. DOI: 10.1038/leu.2009.37. View

12.

Hou H, Kuo Y, Liu C, Chou W, Lee M, Chen C . DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2011; 119(2):559-68. DOI: 10.1182/blood-2011-07-369934. View

13.

Losman J, Kaelin Jr W . What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013; 27(8):836-52. PMC: 3650222. DOI: 10.1101/gad.217406.113. View

14.

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

15.

Jan M, Majeti R . Clonal evolution of acute leukemia genomes. Oncogene. 2012; 32(2):135-40. PMC: 5538364. DOI: 10.1038/onc.2012.48. View

16.

Metzeler K, Walker A, Geyer S, Garzon R, Klisovic R, Bloomfield C . DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2011; 26(5):1106-7. PMC: 3696987. DOI: 10.1038/leu.2011.342. View

17.

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O . Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147-52. DOI: 10.1038/leu.2011.71. View

18.

Shih A, Abdel-Wahab O, Patel J, Levine R . The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12(9):599-612. DOI: 10.1038/nrc3343. View

19.

He Y, Li B, Li Z, Liu P, Wang Y, Tang Q . Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011; 333(6047):1303-7. PMC: 3462231. DOI: 10.1126/science.1210944. View

20.

Jan M, Snyder T, Corces-Zimmerman M, Vyas P, Weissman I, Quake S . Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012; 4(149):149ra118. PMC: 4045621. DOI: 10.1126/scitranslmed.3004315. View